Sarilumab per al tractament de l'artritis reumatoide activa, de moderada a greu en pacients adults quan la resposta als fàrmacs antireumàtics modificadors de la malaltia (FAMM) inclòs el metotrexat (MTX) ha estat inadequada
Abstract
Rheumatoid arthritis (AR) is a chronic systemic autoimmune disease that is a serious cause of unknown etiology that mainly affects synovial joints although it can also be used with systemic manifestations. Rheumatoid arthritis typically manifests as a polyarticular disease and a gradual onset. It occurs in the form of sprouts with joint inflammation, stiffness and pain initially in peripheral joints (joints of hands and feet) and as it progresses it can also affect the most proximal joints. In patients with uncontrolled AR, inflammation leads to progressive and irreversible joint destruction due to erosion of the cartilage and the bear, producing joint deformities. Patients with extraarticular manifestations may present anorexia, subcutaneous nodules, serositis, vasculitis or uveitis
Keywords
Active rheumatoid arthritis; Sarilumab; Adult patients
Bibliographic citation
Programa d'harmonització farmacoterapèutica. Sarilumab per al tractament de l'artritis reumatoide activa, de moderada a greu en pacients adults quan la resposta als fàrmacs antireumàtics modificadors de la malaltia (FAMM) inclòs el metotrexat (MTX) ha estat inadequada. Barcelona: Servei Català de la Salut; 2018.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4281This item appears in following collections
The following license files are associated with this item: